These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 36548543

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging.
    Wucherpfennig L, Wuennemann F, Eichinger M, Seitz A, Baumann I, Stahl M, Graeber SY, Zhao S, Chung J, Schenk JP, Alrajab A, Kauczor HU, Mall MA, Sommerburg O, Wielpütz MO.
    Front Pharmacol; 2023; 14():1161891. PubMed ID: 37101549
    [Abstract] [Full Text] [Related]

  • 3. Elexacaftor/tezacaftor/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor/ivacaftor.
    Wucherpfennig L, Becker JKZ, Wuennemann F, Eichinger M, Seitz A, Baumann I, Stahl M, Graeber SY, Zhao S, Chung J, Schenk JP, Alrajab A, Kauczor HU, Mall MA, Sommerburg O, Wielpütz MO.
    J Cyst Fibros; 2024 Mar; 23(2):234-241. PubMed ID: 38218661
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis.
    Wucherpfennig L, Triphan SMF, Wege S, Kauczor HU, Heussel CP, Schmitt N, Wuennemann F, Mayer VL, Sommerburg O, Mall MA, Eichinger M, Wielpütz MO.
    J Cyst Fibros; 2022 Nov; 21(6):1053-1060. PubMed ID: 35400600
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY, Boutin S, Wielpütz MO, Joachim C, Frey DL, Wege S, Sommerburg O, Kauczor HU, Stahl M, Dalpke AH, Mall MA.
    Ann Am Thorac Soc; 2021 Jun; 18(6):971-980. PubMed ID: 33600745
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F.
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [Abstract] [Full Text] [Related]

  • 10. A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.
    Rayment JH, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M, Paz-Diaz H, Tian S, Zahigian R, McColley SA.
    Am J Respir Crit Care Med; 2022 Nov 15; 206(10):1239-1247. PubMed ID: 35771568
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS.
    Lancet Respir Med; 2019 Apr 15; 7(4):325-335. PubMed ID: 30686767
    [Abstract] [Full Text] [Related]

  • 13. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles.
    Graeber SY, Renz DM, Stahl M, Pallenberg ST, Sommerburg O, Naehrlich L, Berges J, Dohna M, Ringshausen FC, Doellinger F, Vitzthum C, Röhmel J, Allomba C, Hämmerling S, Barth S, Rückes-Nilges C, Wielpütz MO, Hansen G, Vogel-Claussen J, Tümmler B, Mall MA, Dittrich AM.
    Am J Respir Crit Care Med; 2022 Aug 01; 206(3):311-320. PubMed ID: 35536314
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC, VX14-809-109 investigator group.
    Lancet Respir Med; 2017 Jul 01; 5(7):557-567. PubMed ID: 28606620
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
    Moheet A, Beisang D, Zhang L, Sagel SD, VanDalfsen JM, Heltshe SL, Frederick C, Mann M, Antos N, Billings J, Rowe SM, Moran A, PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network.
    J Cyst Fibros; 2021 Mar 01; 20(2):333-338. PubMed ID: 32917547
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
    Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA.
    Lancet Respir Med; 2021 Sep 01; 9(9):977-988. PubMed ID: 33965000
    [Abstract] [Full Text] [Related]

  • 19. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE, Farzal Z, Daniels MLA, Thorp BD, Zanation AM, Senior BA, Ebert CS, Kimple AJ.
    Am J Rhinol Allergy; 2020 Jul 01; 34(4):573-580. PubMed ID: 32168995
    [Abstract] [Full Text] [Related]

  • 20. Elexacaftor/Tezacaftor/Ivacaftor Improves Bronchial Artery Dilatation Detected by Magnetic Resonance Imaging in Patients with Cystic Fibrosis.
    Wucherpfennig L, Triphan SMF, Wege S, Kauczor HU, Heussel CP, Sommerburg O, Stahl M, Mall MA, Eichinger M, Wielpütz MO.
    Ann Am Thorac Soc; 2023 Nov 01; 20(11):1595-1604. PubMed ID: 37579262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.